sodium salt of pravastatin (pravastatinum natricum)
- reduction of hyperlipidemia occurring in transplant patients receiving immunosuppressive therapy following solid organ transplantation,
- therapy of primary hypercholesterolemia or mixed dyslipidemia as an adjunct therapy to diet when the response to diet and other non-pharmacological treatments (eg .: exercise, weight body) is insufficient,
- reducing the mortality and morbidity of cardiovascular disease in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet
- reducing the mortality and morbidity of cardiovascular disease in Patients with myocardial infarction or unstable angina pectoris and with normal or increased cholesterol levels, as an adjunct to correct other risk factors.
Included in the preparation of pravastatin is a competitive inhibitor of the reductase 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme catalyzing the early stage of cholesterol biosynthesis, and two ways of decreasing the amount of lipids. Stops production of LDL-cholesterol in the liver by blocking the synthesis of VLDL-cholesterol, LDL-cholesterol precursor. As a reversible and specific inhibitor competing with the HMG-CoA reductase in a small reduces the intracellular synthesis of cholesterol; this leads to an increase in the number of LDL-cholesterol receptors on the cell surface and increased catabolism and circulating LDL-cholesterol.
- Hypersensitivity to the active substance or to any of the excipients
- active liver disease including unexplained persistent elevations of serum transaminases 3 times the upper limit of normal
- pregnancy and lactation
Oral. You should select individual dosage depends on the patient's clinical status.